Literature DB >> 31359421

Thomas J. Dougherty: An Appreciation.

David Kessel1.   

Abstract

Without the efforts of Tom Dougherty, it is unlikely that photodynamic therapy would have been more than a minor biomedical curiosity. His contributions to the field not only involved demonstrating the clinical relevance of the procedure but organizing that eventually led to FDA approval. This report summarizes his contributions to the field and illustrates the scope of discoveries that became feasible after his work brought PDT to the attention of others and to assorted funding agencies.
© 2019 American Society for Photobiology.

Entities:  

Year:  2019        PMID: 31359421     DOI: 10.1111/php.13144

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  2 in total

1.  Bis[pyrrolyl Ru(ii)] triads: a new class of photosensitizers for metal-organic photodynamic therapy.

Authors:  Deborah A Smithen; Susan Monro; Mitch Pinto; John Roque; Roberto M Diaz-Rodriguez; Huimin Yin; Colin G Cameron; Alison Thompson; Sherri A McFarland
Journal:  Chem Sci       Date:  2020-10-06       Impact factor: 9.825

2.  Near-infrared absorbing Ru(ii) complexes act as immunoprotective photodynamic therapy (PDT) agents against aggressive melanoma.

Authors:  Liubov M Lifshits; John A Roque Iii; Prathyusha Konda; Susan Monro; Houston D Cole; David von Dohlen; Susy Kim; Gagan Deep; Randolph P Thummel; Colin G Cameron; Shashi Gujar; Sherri A McFarland
Journal:  Chem Sci       Date:  2020-09-09       Impact factor: 9.825

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.